| abstract |
The present disclosure relates to thrombin antibodies, antigen-binding fragments thereof, and medical uses. Further, the present disclosure relates to murine antibodies, chimeric antibodies, humanized antibodies comprising the CDR regions of the thrombin antibody, and pharmaceutical compositions comprising the thrombin antibody and/or antigen-binding fragments thereof, and their use as medicines. use. In particular, the present disclosure relates to the use of a humanized thrombin antibody in the manufacture of a medicament for the treatment of a thrombin-related disease or disorder. |